JUPITER NEUROSCIENCES INC

Company Overview

Jupiter Neurosciences (JUNS) is a clinical‑stage biotechnology company developing JOTROL™, an oral micellar resveratrol formulation being repurposed across neurological and rare‑disease indications (lead near‑term programs in Parkinson’s disease and mild cognitive impairment/early Alzheimer’s, plus several orphan programs). The company operates as a virtual, capital‑efficient organization with a very small core team and outsources R&D, manufacturing (Catalent) and regulatory support, while relying on an exclusive license from Aquanova and planned out‑licensing in Southeast Asia. Key near‑term catalysts are a mid‑to‑late‑2025 Phase IIa Parkinson’s start and a pending $16.5M NIA grant decision, while material risks include limited cash runway, dependence on third‑party partners and patent/regulatory outcomes.

Executive Compensation Practices

Compensation at JUNS is heavily equity‑linked: stock‑based compensation rose materially (about $1.84M in 2024 and roughly $984k included in 2025 YTD figures), reflecting a cash‑constrained company using options/awards to conserve cash while attracting talent. Cash salaries were reduced in late 2023 and management has emphasized tight G&A control, but R&D and G&A spend spiked in 2025 as the company scales for clinical activity and public‑company costs; this makes future pay decisions sensitive to capital raises, milestone funding (grants, licensing), and clinical progress. Given the firm’s small headcount, related‑party arrangements (CEO loans, amounts due to the CFO’s company) and equity‑for‑services deals in Asia, a large share of executive compensation and advisor remuneration may be delivered via share issuances or convertible instruments rather than cash.

Insider Trading Considerations

As a thin‑floated, small‑cap biotech with large upcoming binary events (grant decision, IND/FDA interactions, Phase II start and later readouts), JUNS’s stock is likely to be highly volatile around those milestones, so insider trades will be particularly market‑sensitive and closely watched. Insiders must comply with Section 16 and Form 4 timing (2 business days) and usual IPO lockup/blackout expectations; many company insiders in this situation adopt Rule 10b5‑1 plans to pre‑schedule sales given frequent material non‑public catalysts. Additionally, frequent equity issuances (equity‑for‑services, financing, and convertible debt conversions) increase dilution risk and can alter insider ownership patterns, so researchers should monitor Form 4/8‑K filings for share grants, related‑party transactions and participation in financings as signals of insider liquidity needs or confidence.